DISHMAN PHARMA | SUVEN LIFE SCIENCES | DISHMAN PHARMA/ SUVEN LIFE SCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | -83.9 | - | View Chart |
P/BV | x | 3.3 | 1.3 | 254.1% | View Chart |
Dividend Yield | % | 0.7 | 1.7 | 38.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
SUVEN LIFE SCIENCES Mar-19 |
DISHMAN PHARMA/ SUVEN LIFE SCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 338 | 110.9% | |
Low | Rs | 129 | 169 | 76.1% | |
Sales per share (Unadj.) | Rs | 197.8 | 52.1 | 379.4% | |
Earnings per share (Unadj.) | Rs | 21.2 | 6.8 | 310.4% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 8.6 | 405.1% | |
Dividends per share (Unadj.) | Rs | 2.00 | 1.50 | 133.3% | |
Dividend yield (eoy) | % | 0.8 | 0.6 | 134.3% | |
Book value per share (Unadj.) | Rs | 179.9 | 65.3 | 275.5% | |
Shares outstanding (eoy) | m | 80.69 | 127.28 | 63.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 4.9 | 26.2% | |
Avg P/E ratio | x | 11.9 | 37.1 | 32.0% | |
P/CF ratio (eoy) | x | 7.2 | 29.6 | 24.5% | |
Price / Book Value ratio | x | 1.4 | 3.9 | 36.0% | |
Dividend payout | % | 9.4 | 22.0 | 42.9% | |
Avg Mkt Cap | Rs m | 20,306 | 32,272 | 62.9% | |
No. of employees | `000 | 0.8 | 1.1 | 76.6% | |
Total wages/salary | Rs m | 5,355 | 661 | 809.9% | |
Avg. sales/employee | Rs Th | 19,252.7 | 6,132.2 | 314.0% | |
Avg. wages/employee | Rs Th | 6,459.5 | 611.1 | 1,057.0% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 803.5 | 256.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 6,635 | 240.6% | |
Other income | Rs m | 265 | 242 | 109.5% | |
Total revenues | Rs m | 16,226 | 6,877 | 235.9% | |
Gross profit | Rs m | 4,103 | 1,604 | 255.8% | |
Depreciation | Rs m | 1,091 | 221 | 492.6% | |
Interest | Rs m | 944 | 38 | 2,505.0% | |
Profit before tax | Rs m | 2,334 | 1,587 | 147.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 718 | 86.9% | |
Profit after tax | Rs m | 1,711 | 869 | 196.8% | |
Gross profit margin | % | 25.7 | 24.2 | 106.3% | |
Effective tax rate | % | 26.7 | 45.2 | 59.1% | |
Net profit margin | % | 10.7 | 13.1 | 81.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 6,232 | 176.8% | |
Current liabilities | Rs m | 9,517 | 1,490 | 638.7% | |
Net working cap to sales | % | 9.4 | 71.5 | 13.2% | |
Current ratio | x | 1.2 | 4.2 | 27.7% | |
Inventory Days | Days | 110 | 86 | 127.8% | |
Debtors Days | Days | 35 | 83 | 42.2% | |
Net fixed assets | Rs m | 16,304 | 4,043 | 403.2% | |
Share capital | Rs m | 161 | 127 | 126.8% | |
"Free" reserves | Rs m | 12,907 | 8,183 | 157.7% | |
Net worth | Rs m | 14,516 | 8,310 | 174.7% | |
Long term debt | Rs m | 4,189 | 18 | 23,536.0% | |
Total assets | Rs m | 29,805 | 10,389 | 286.9% | |
Interest coverage | x | 3.5 | 43.1 | 8.1% | |
Debt to equity ratio | x | 0.3 | 0 | 13,474.0% | |
Sales to assets ratio | x | 0.5 | 0.6 | 83.8% | |
Return on assets | % | 8.9 | 8.7 | 102.0% | |
Return on equity | % | 11.8 | 10.5 | 112.7% | |
Return on capital | % | 17.5 | 19.5 | 89.8% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 5,622 | 88.1% | |
Fx outflow | Rs m | 697 | 1,799 | 38.7% | |
Net fx | Rs m | 4,255 | 3,822 | 111.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 356 | 783.8% | |
From Investments | Rs m | -1,529 | -279 | 548.8% | |
From Financial Activity | Rs m | -941 | -225 | 418.1% | |
Net Cashflow | Rs m | 316 | -148 | -213.5% |
Indian Promoters | % | 61.4 | 63.4 | 96.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 0.0 | - | |
FIIs | % | 12.7 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 36.5 | 60.5% | |
Shareholders | 46,261 | 37,287 | 124.1% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: GLENMARK PHARMA FULFORD INDIA PROCTER & GAMBLE HEALTH DIVIS LABORATORIES UNICHEM LAB
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.
For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.
For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.
For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More